Valantine Hannah — SEC Form 4 filings
SEC reporting owner CIK 1855608. 23 Form 4 filings on record with FilingPulse; latest filed 2026-07-17.
Transaction summary — filings shown
Covers all 23 filings on record, filed 2024-01-18 to 2026-07-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 3 filings — 7,523 shares, $99,452 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 18 legs across 12 filings — 143,799 shares, $6,909,112 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 36.
- Largest priced transaction: sale of 25,484 shares @ $66.07 ($1,683,728) in BridgeBio Pharma, Inc., filed 2025-11-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | Director | 14 | 5 legs · 7,523 sh · $99,452 | 14 legs · 92,347 sh · $5,386,575 | 21 |
| CareDx, Inc. (CDNA) | Director | 6 | — | 4 legs · 51,452 sh · $1,522,537 | 11 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | Director | 3 | — | — | 4 |
Form 4 filings — Valantine Hannah
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-17 | 4 | CareDx, Inc. (CDNA) | Option exercise (M): 7,606 @ $20.56 · Option exercise (M): 16,048 @ $14.19 · Option exercise (M): 5,125 @ $7.96 · Sale (S): 28,679 @ $36.14 · Sale (S): 100 @ $36.55 · Option exercise (M): 7,606 (derivative) @ $0 · +2 more | EDGAR |
| 2026-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 3,990 @ $0 · Option exercise (M): 2,808 @ $41.73 · Sale (S): 2,808 @ $68 · Sale (S): 2,196 @ $68.57 · Grant/award (A): 5,277 (derivative) @ $0 · Option exercise (M): 2,808 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | CareDx, Inc. (CDNA) | Grant/award (A): 9,795 @ $0 · Sale (S): 12,103 @ $23.11 | EDGAR |
| 2026-06-04 | 4 | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | Grant/award (A): 223,492 (derivative) @ $0 | EDGAR |
| 2026-03-12 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 8,671 @ $27.36 · Sale (S): 8,671 @ $72 · Option exercise (M): 8,671 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 25,484 @ $48.45 · Sale (S): 14,584 @ $67.08 · Sale (S): 10,900 @ $67.84 · Option exercise (M): 25,484 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 25,484 @ $48.45 · Sale (S): 25,484 @ $66.07 · Option exercise (M): 25,484 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4/A | BridgeBio Pharma, Inc. (BBIO) | Purchase (P): 1,542 @ $12.68 · Purchase (P): 796 @ $13.16 | EDGAR |
| 2025-06-30 | 4/A | BridgeBio Pharma, Inc. (BBIO) | Purchase (P): 1,752 @ $14.24 | EDGAR |
| 2025-06-30 | 4 | BridgeBio Pharma, Inc. (BBIO) | Sale (S): 876 @ $44.11 · Sale (S): 1,542 @ $44.01 · Sale (S): 398 @ $44.13 · Sale (S): 1,891 @ $44.03 | EDGAR |
| 2025-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 6,589 @ $0 · Grant/award (A): 8,425 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | CareDx, Inc. (CDNA) | Sale (S): 10,570 @ $19.16 | EDGAR |
| 2025-06-17 | 4 | CareDx, Inc. (CDNA) | Grant/award (A): 12,103 @ $0 | EDGAR |
| 2025-06-11 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 4,292 @ $16.75 · Sale (S): 4,292 @ $40 · Option exercise (M): 4,292 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 12,875 @ $16.75 · Sale (S): 12,875 @ $32.58 · Option exercise (M): 12,875 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 26,014 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4/A | CareDx, Inc. (CDNA) | Grant/award (A): 16,048 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | Grant/award (A): 22,821 @ $0 · Grant/award (A): 32,179 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | CareDx, Inc. (CDNA) | Grant/award (A): 10,570 @ $0 · Grant/award (A): 16,048 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 2,915 @ $8.45 · Sale (S): 2,915 @ $37.75 · Option exercise (M): 2,915 (derivative) @ $0 | EDGAR |
| 2024-02-13 | 4 | BridgeBio Pharma, Inc. (BBIO) | Purchase (P): 1,891 @ $13.18 · Purchase (P): 1,542 @ $12.68 | EDGAR |
| 2024-01-18 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 2,915 @ $8.45 · Sale (S): 2,915 @ $37.97 · Option exercise (M): 2,915 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1855608 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →